Komen North Texas Goes to Austin
Last month, Komen North Texas Mission Programs Manager, Cathreena Kang, joined other Texas Komen Affiliates at the 2017 Texas Advocacy Day at the State Capitol. Komen staff, survivors, volunteers and grantees visited with their local State Senators and Representatives to advocate for continued support of life-saving breast health services and research. Specifically, advocates asked legislators to:
- Preserve funding and maintain eligibility for the Breast and Cervical Cancer Services program in the FY 2018-2019 budget
- Support House Bill 195 to ensure patients have access to necessary diagnostic mammography
- Fully fund the Cancer and Research Institute of Texas (CPRIT) at $600 million in the FY 2018-2019 budget.
The Affiliate spoke to legislators and/or staff from the offices of State Representative Jeff Leach, Senator Jane Nelson, State Representative Tan Parker, Lieutenant Governor Dan Patrick, State Representative Justin Holland, Representative Matt Shaheen, Senator Van Taylor and Representative Lynn Stucky.
Komen North Texas invites you to contact your local legislator with these same messages to help us fight breast cancer in our community. Click here to find out who your State Senator and Representative at the Capitol: http://www.fyi.legis.state.tx.us/Home.aspx
For more information, please contact Cathreena Kang to get involved in our advocacy efforts.
About Komen Advocacy
About the Breast and Cervical Cancer Services Program
The Breast and Cervical Cancer Services Program (BCCS) served 34,376 women and diagnosed more than 328 breast cancers in 2015. With the state’s decision not to expand Medicaid, the BCCS program is more vital than ever. More than 1.7 million uninsured Texas women will continue to struggle without access to affordable health coverage. The availability of the BCCS program impacts every Texas taxpayer, as the uninsured will eventually show up at our state’s hospitals with late-stage diagnoses, putting an even greater strain on the health system and state budgets. Ensuring the BCCS program remains adequately funded will be key to ensuring low-income, uninsured women continue to have access to vital screening services as well as ensuring newly uninsured women have access to health education, case management and patient navigation services.
About the Cancer and Research Institute of Texas
The mission of the Cancer and Research Institute of Texas (CPRIT) is to create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of cancer and cures for cancer, and attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in this state. CPRIT has issued more than 1,110 grants totaling more than $1.76 billion for research and prevention in the state of Texas. Since its inception, the CPRIT prevention program has supported more than 826,871 screenings and diagnostics for breast, cervical and colorectal cancer. CPRIT enabled the recruitment of 127 cancer researchers and their labs to Texas. Ensuring CPRIT remains fully funded will be key to ensuring Texas remains the leader in cancer research and prevention.
About Diagnostic Mammography
Diagnostic mammography is coded differently than a screening mammogram, and is typically more expensive because additional x-rays are required to obtain views of the breast from several angles. Patients may be required to pay higher co-pays, coinsurance, and other cost-sharing mechanisms when receiving diagnostic mammograms. If women are unable to afford the out-of-pocket costs, many might delay or forgo follow-up screenings, leading to later diagnoses. This delay can mean that women will not seek care until the cancer has spread beyond the breast making it more difficult to treat and more costly to treat. Reducing out-of-pocket costs for diagnostic mammography would improve access and allow more timely diagnosis and treatment of breast cancer.